Autor: "DeSilva MB" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024.
Autorzy:: Link-Gelles R
Rowley EAK
DeSilva MB
Dascomb K
Irving SA
Klein NP
Grannis SJ
Ong TC
Weber ZA
Fleming-Dutra KE
McEvoy CE
Akinsete O
Bride D
Sheffield T
Naleway AL
Zerbo O
Fireman B
Hansen J
Goddard K
Dixon BE
Rogerson C
Fadel WF
Duszynski T
Rao S
Barron MA
Reese SE
Ball SW
Dunne MM
Natarajan K
Okwuazi E
Shah AB
Wiegand R
Tenforde MW
Payne AB; Pokaż więcej
Źródło:: MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2024 Mar 28; Vol. 73 (12), pp. 271-276. Date of Electronic Publication: 2024 Mar 28.
Typ publikacji:: Journal Article
MeSH Terms:: Influenza, Human*/epidemiology
Influenza Vaccines*
COVID-19*/epidemiology
COVID-19*/prevention & control
Adult ; United States/epidemiology ; Humans ; Adolescent ; COVID-19 Vaccines ; Vaccination ; Hospitalization

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Risk of COVID-19 Hospitalization and Protection Associated With mRNA Vaccination Among US Adults With Psychiatric Disorders.
Autorzy:: Levy ME; Westat, Rockville, Maryland, USA.; Helix, San Mateo, California, USA.
Yang DH; Westat, Rockville, Maryland, USA.
Dunne MM; Westat, Rockville, Maryland, USA.
Miley K; HealthPartners Institute, Minneapolis, Minnesota, USA.
Irving SA; Kaiser Permanente Center for Health Research, Portland, Oregon, USA.
Grannis SJ; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.; School of Medicine, Indiana University, Indianapolis, Indiana, USA.
Weber ZA; Westat, Rockville, Maryland, USA.
Griggs EP; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Spark TL; Westat, Rockville, Maryland, USA.
Bassett E; Westat, Rockville, Maryland, USA.
Embi PJ; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.; Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Gaglani M; Baylor Scott & White Health, Temple, Texas, USA.; Texas A&M University College of Medicine, Temple, Texas, USA.
Natarajan K; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.; New York Presbyterian Hospital, New York, New York, USA.
Valvi NR; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.
Ong TC; School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Naleway AL; Kaiser Permanente Center for Health Research, Portland, Oregon, USA.
Stenehjem E; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA.
Klein NP; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California, USA.
Link-Gelles R; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
DeSilva MB; HealthPartners Institute, Minneapolis, Minnesota, USA.
Kharbanda AB; Children's Minnesota, Minneapolis, Minnesota, USA.
Raiyani C; Baylor Scott & White Health, Temple, Texas, USA.
Beaton MA; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.
Dixon BE; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.; Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana, USA.
Rao S; School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Dascomb K; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA.
Patel P; Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Mamawala M; Baylor Scott & White Health, Temple, Texas, USA.
Han J; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.
Fadel WF; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.; Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana, USA.
Barron MA; School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Grisel N; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA.
Dickerson M; Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Liao IC; Baylor Scott & White Health, Temple, Texas, USA.
Arndorfer J; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA.
Najdowski M; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Murthy K; Baylor Scott & White Health, Temple, Texas, USA.
Ray C; Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Tenforde MW; Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Ball SW; Westat, Rockville, Maryland, USA.; Pokaż więcej
Źródło:: Influenza and other respiratory viruses [Influenza Other Respir Viruses] 2024 Mar; Vol. 18 (3), pp. e13269.
Typ publikacji:: Journal Article
MeSH Terms:: COVID-19*/epidemiology
COVID-19*/prevention & control
Mental Disorders*/epidemiology
Adult ; Humans ; COVID-19 Vaccines ; Retrospective Studies ; Vaccination ; Hospitalization ; RNA, Messenger

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States.
Autorzy:: Frutos AM
Price AM
Harker E
Reeves EL
Ahmad HM
Murugan V
Martin ET
House S
Saade EA
Zimmerman RK
Gaglani M
Wernli KJ
Walter EB
Michaels MG
Staat MA
Weinberg GA
Selvarangan R
Boom JA
Klein EJ
Halasa NB
Ginde AA
Gibbs KW
Zhu Y
Self WH
Tartof SY
Klein NP
Dascomb K
DeSilva MB
Weber ZA
Yang DH
Ball SW
Surie D
DeCuir J
Dawood FS
Moline HL
Toepfer AP
Clopper BR
Link-Gelles R
Payne AB
Chung JR
Flannery B
Lewis NM
Olson SM
Adams K
Tenforde MW
Garg S
Grohskopf LA
Reed C
Ellington S; Pokaż więcej
Corporate Authors:: CDC Influenza Vaccine Effectiveness Collaborators
Źródło:: MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2024 Feb 29; Vol. 73 (8), pp. 168-174. Date of Electronic Publication: 2024 Feb 29.
Typ publikacji:: Journal Article
MeSH Terms:: Influenza Vaccines*
Influenza, Human*/epidemiology
Influenza, Human*/prevention & control
Adolescent ; Adult ; Humans ; Child ; Seasons ; Case-Control Studies ; Vaccine Efficacy

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years - VISION and IVY Networks, September 2023-January 2024.
Autorzy:: DeCuir J
Payne AB
Self WH
Rowley EAK
Dascomb K
DeSilva MB
Irving SA
Grannis SJ
Ong TC
Klein NP
Weber ZA
Reese SE
Ball SW
Barron MA
Naleway AL
Dixon BE
Essien I
Bride D
Natarajan K
Fireman B
Shah AB
Okwuazi E
Wiegand R
Zhu Y
Lauring AS
Martin ET
Gaglani M
Peltan ID
Brown SM
Ginde AA
Mohr NM
Gibbs KW
Hager DN
Prekker M
Mohamed A
Srinivasan V
Steingrub JS
Khan A
Busse LW
Duggal A
Wilson JG
Chang SY
Mallow C
Kwon JH
Exline MC
Columbus C
Vaughn IA
Safdar B
Mosier JM
Harris ES
Casey JD
Chappell JD
Grijalva CG
Swan SA
Johnson C
Lewis NM
Ellington S
Adams K
Tenforde MW
Paden CR
Dawood FS
Fleming-Dutra KE
Surie D
Link-Gelles R; Pokaż więcej
Corporate Authors:: CDC COVID-19 Vaccine Effectiveness Collaborators
Źródło:: MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2024 Feb 29; Vol. 73 (8), pp. 180-188. Date of Electronic Publication: 2024 Feb 29.
Typ publikacji:: Journal Article
MeSH Terms:: COVID-19 Vaccines*
COVID-19*/epidemiology
COVID-19*/prevention & control
Adult ; Humans ; Adolescent ; Advisory Committees ; Emergency Service, Hospital ; Hospitalization

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Effectiveness of the Original Monovalent Coronavirus Disease 2019 Vaccines in Preventing Emergency Department or Urgent Care Encounters and Hospitalizations Among Adults With Disabilities: VISION Network, June 2021-September 2022.
Autorzy:: Patel P; Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Schrader KE; Department of Clinical Research, Westat, Rockville, Maryland, USA.
Rice CE; Division of Human Development and Disability, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Rowley E; Department of Clinical Research, Westat, Rockville, Maryland, USA.
Cree RA; Division of Human Development and Disability, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
DeSilva MB; Department of Research, Health Partners Institute, Minneapolis, Minnesota, USA.
Embi PJ; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Gaglani M; Section of Pediatric Infectious Diseases, Department of Pediatrics, Baylor Scott & White Health, Temple, Texas, USA.; Department of Medical Education, Texas A&M University College of Medicine, Temple, Texas, USA.
Grannis SJ; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.; School of Medicine, Indiana University, Indianapolis, Indiana, USA.
Ong TC; School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Stenehjem E; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA.
Naleway AL; Department of Science Programs, Kaiser Permanente Center for Health Research, Portland, Oregon, USA.
Ball S; Department of Clinical Research, Westat, Rockville, Maryland, USA.
Natarajan K; Department of Biomedical Informatics, Columbia University Irving Medical Center, NewYork, New York, USA.; Medical Informatics Services, NewYork-Presbyterian Hospital, NewYork, New York, USA.
Klein NP; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California, USA.
Adams K; Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Kharbanda A; Department of Emergency Medicine, Children's Minnesota, Minneapolis, Minnesota, USA.
Ray C; Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Link-Gelles R; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Tenforde MW; Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; Pokaż więcej
Źródło:: Open forum infectious diseases [Open Forum Infect Dis] 2023 Sep 29; Vol. 10 (11), pp. ofad474. Date of Electronic Publication: 2023 Sep 29 (Print Publication: 2023).
Typ publikacji:: Journal Article